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ABSTRACT 
Enteroviruses are common viruses which cause infections in humans that usually result in 
mild flu-like symptoms before viral clearance.  However, in some cases these infections can 
progress to more severe diseases such as myocarditis, pancreatitis and hepatitis. 
Coxsackievirus induced hepatitis in infants may become so severe that the outcome is fatal. 
In addition, infections with enteroviruses belonging to the group B Coxsackieviruses have 
been implicated in the etiology of type 1 diabetes. Enterovirus infections are also commonly 
observed in patients with cystic fibrosis, resulting in lung exacerbations and morbidity.  
Proper antiviral response mechanisms are crucial for the prevention of viral replication and 
spread, as well as the inhibition of virus induced cellular damage. Recently a novel group of 
interferons, called type III interferons, were discovered and shown to have antiviral properties 
predominantly in cells of epithelial origin. In Paper I we show that type III interferons protect 
primary human hepatocytes from Coxsackievirus infection. Given the importance of 
interferons in preventing early viral replication, many viruses have developed mechanisms to 
inhibit their induction. In Paper II, we showed that Coxsackieviruses inhibit the induction of 
type III interferons in infected cells. In addition, we demonstrated that this inhibition was 
caused by the proteolytic activity of the viral protease 2Apro. The exact role of enterovirus 
infections in type 1 diabetes development is still under speculation. Coxsackieviruses encodes 
several viral proteins that have been shown to interfere with cellular function and signaling 
pathways. In Paper III, we used primary human pancreatic islets and an insulin-secreting cell 
line to identify mechanisms by which Coxsackeiviruses can cause beta cell dysfunction. We 
found that the viral proteins 2Apro, 3A and 3Cpro could, independently of one other, affect 
exocytosis with 2Apro and 3Cpro targeting calcium influx while 3A inhibited exocytosis via a 
calcium independent mechanism. An impaired antimicrobial defense has been observed in 
patients with cystic fibrosis. This could explain why common respiratory infections are often 
prolonged and more severe in these patients. By using a mouse model for cystic fibrosis, we 
showed in Paper IV that the most common mutation resulting in cystic fibrosis, F508del, 
caused an impaired adaptive immune response with a delayed production of neutralizing 
antibodies to Coxsackievirus.  
In conclusion, the studies performed in this thesis add to our understanding of innate and 
adaptive immune response mechanisms during Coxackievirus infections. In addition they 
demonstrate a role for viral proteins in circumventing host antiviral immune responses, thus 
causing cellular damage, which could contribute to disease pathology. Increasing the 
knowledge of host-pathogen interactions may help to develop new treatments that could 
prevent severe Coxsackievirus infections. 
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1 INTRODUCTION 
Our body is constantly fighting a never-ending battle against pathogens that are trying to 
invade our body. To defend ourselves, we have evolved several protective mechanisms that 
together constitute the immune system. The discovery that viruses are infectious agents which 
are capable of transferring and spreading disease was made in late 1800 when Dmitry 
Ivanovsky showed that a bacteria-free filtrate from an infected tobacco plant could still 
transfer disease to a healthy plant (1). A few yeas later, Martinus Beijerinck repeated these 
experiments and concluded that the disease must be caused by a new type of infectious agent 
which was subsequently named “virus” after the Latin word for poison (1). Today, over 5000 
virus species have been discovered. Viruses can infect all living things including animals, 
plants and bacteria. However, as they are small parasites they cannot reproduce by 
themselves and require the replication machinery of living cells in order to spread (2).  
Increasing our knowledge regarding host antiviral immune response mechanisms and how 
viruses circumvent these mechanisms, thereby causing cellular damage will hopefully 
provide clues on how viruses are triggering disease and insight on how to develop new 
antiviral therapies. This thesis is based on four papers in which I have studied the importance 
of type III interferons in regulating permissiveness to a Coxsackievirus infection in primary 
human hepatocytes (Paper I) and how Coxsackieviruses utilize virus encoded proteins to 
evade the type III interferon response (Paper II). In addition, I have looked at how 
Coxsackievirus encoded proteins can cause beta cell dysfunction after infection (Paper III) 
and how the adaptive immune response to Coxsackieviruses is affected by mutations in the 
cystic fibrosis transmembrane conductance regulator protein (Paper IV). A brief introduction 
to the field will follow to broaden the understanding of the concepts presented in Papers I-
IV.  
1.1 ENTEROVIRUSES 
All viruses can be subdivided into different classes based on their similarities. One of the 
most common types of viral infection in humans is that caused by viruses belonging to the 
enterovirus (EV) genus. These viruses carry their genome as a small positive single stranded 
RNA molecule and usually infect via the enteric, i.e. intestinal, route (2). The RNA genome 
is surrounded by a capsid which is highly resistant to environmental exposure such as drying 
and low pH from stomach acid (1). EVs can use a broad range of molecules on the cell 
surface as receptors for viral entry (3). Due to the specificity for certain receptors, different 
viruses within the EV genus usually have distinct target organs which they can infect and 
induce pathology.  
1.1.1 Coxsackievirus group B 
Coxsackievirus group B (CVB) belongs to the EV genus and comprises of six different 
serotypes, CVB 1-6 (4). CVBs infect cells via the Coxsackievirus and adenovirus receptor 
(CAR) (5), which is part of the tight junction complex that mediates cellular adhesion in a 
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number of tissues such as heart and epithelial cells of the gut (6-8). In addition, studies have 
shown that certain serotypes of CVB can also infect via decay acceleration factor (DAF), 
which is a protein that regulates activation of the complement system (9, 10). Infections with 
CVBs are very common and are usually associated with mild flu-like symptoms. However, 
they can in some cases give rise to more severe diseases such as myocarditis, hepatitis, 
pancreatitis and meningitis, with CVB infections being the most common cause of aseptic 
meningitis in children (2). In addition, several studies have suggested that CVBs may be 
involved in the etiology of type 1 diabetes (T1D) (11, 12).  
1.1.1.1 CVB replication and host cell interactions  
After CVB enters the host and has attached to the viral receptors CAR or DAF on target cells, 
it is internalized via endocytosis (13). Once inside the cell, the CVB genome is uncoated and 
exposed to the cytoplasmic contents. The positive RNA strand can immediately be translated 
by the cellular ribosome into a single viral polyprotein. The polyprotein encodes four 
structural proteins (VP1-4) and seven non-structural proteins (2A-C and 3A-D) which are all 
important for viral replication (14). Among the non-structural proteins are two viral proteases 
2Apro and 3Cpro which are responsible for viral maturation and, upon translation, will cleave 
the viral polyprotein into separate functional viral proteins (15-17). Once the viral proteins 
are formed, the virus can start to replicate in the cytoplasm. This replication takes place on 
rearranged cellular membranes that are derived from the endoplasmic reticulum (ER) and 
Golgi (14).  
Figure 1: The CVB polyprotein 
Although EVs are small viruses that only carry a very limited number of proteins, several of 
these viral proteins have been shown to have multiple functions within the infected cell.  For 
example, in addition to cleaving the viral polyprotein, the proteases can also target several 
cellular proteins. One target for 2Apro, is the eukaryotic initiation factor 4G (eIF4G) which is 
needed for translation of 5´capped cellular RNA (18). Since viruses do not have a 5´cap but 
instead bind to the ribosome via an internal ribosome entry site  (IRES), CVB is able to 
inhibit cellular protein translation and thus promote the production of viral proteins. 3Cpro has 
been shown to cleave poly C binding protein (PCBP) and through this, it can regulate the 
switch from viral translation to viral replication (19). Furthermore, it has been reported that 
2Apro directly contributes to disease pathology by cleaving dystrophin, resulting in CVB 
induced cardiomyopathy (20, 21). Other viral non-structural proteins with membrane binding 
capacity, like 2B and 3A, can also affect host cell functions by recruiting cellular membranes 
to generate viral replication organelles in the cytoplasm. 2B and 3A target both COPII and 
COPI coated vesicles and inhibit ER to Golgi transport (22, 23). In addition, it has been 
suggested that 3A is important in promoting the binding of the viral polymerase 3D to the 
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membrane of these replication organelles (23). However, the actual need for 3A in this 
process has been debated (24). 
1.2 BASIC IMMUNOLOGY 
To prevent surrounding pathogens from infecting and causing disease, we have developed 
specialized mechanisms to protect ourselves. Collectively, these specialized mechanisms are 
called the immune system (25). The first part of the immune system includes physical 
barriers like the skin and mucosa which prevent pathogens from entering our bodies. If a 
pathogen still manages to break through these barriers and enter the body there are two 
immune response arms that can respond, the fast acting innate immune response and the more 
slowly activated but highly specific adaptive immune response.  
1.2.1 The innate immune system  
The innate immune system provides the first line of defense if a pathogen manages to breach 
the physical barriers and cells belonging to the innate immune system can immediately 
recognize and respond to a pathogen. Cells that can mount an innate immune response 
include macrophages, dendritic cells (DCs), neutrophils and natural killer (NK) cells, which 
are constantly present in the tissue, as well as infected nucleated cells. These cells express 
germ line encoded pattern recognition receptors (PRRs) that are activated in a non-specific 
manner via the recognition of general structures found on pathogens, so called pathogen 
associates molecular patterns (PAMPs) (26). Recognition of such danger signals induces the 
production of cytokines that then attract further immune cells to site of infection and also 
induce the phagocytosis of pathogens. Thus the early activation of the innate immune 
response is important for containing infections and preventing spread. In addition, cells of the 
innate immune system also have an important role in activating the adaptive immune system 
as they are able to process and present antigens to T cells (26). Due to the large variety of 
pathogens, cells have developed a broad range of PRRs which are expressed both 
intracellularly, for recognition of e.g. viruses, and on the cell surface for detection of 
extracellular pathogens such as bacteria.  
1.2.1.1 Recognition of viruses and signaling pathways 
Two major groups of PRRs that are important for the recognition of RNA viruses are the Toll 
like receptor (TLRs) and RIG-I like receptors (RLRs) (27, 28). As many as 10 different TLRs 
have been discovered in humans but only TLR3 and TLR7-9 are expressed in an intracellular 
location on endosomes and endolysosomes (29). Even though TLR2 and TLR4 have also 
been shown to recognize viruses, they seem to be mainly important for the recognition of 
enveloped viruses (30, 31). TRL3 recognizes dsRNA and is important for the detection of 
influenza A virus and CVB3 (32) (33). TLR3 also serves as a sensor of the synthetic RNA 
molecule, Polyinosinic:polycytidylic acid (poly I:C) (34). TLR7-8 recognize ssRNA (35) and 
are also thought to be important in the recognition of influenza A virus and CVB (36, 37). In 
addition, they are stimulated by small synthetic antiviral molecules such as resiquimod 
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(R848) (38). TLR9 is activated by CpG molecules, which originate from by DNA viruses and 
bacteria (39).  
RLRs include three members, retinoic acid inducible gene I (RIG-I), melanoma 
differentiation associated protein 5 (MDA5) and laboratory of genetics and physiology 2 
(LGP2) which are all expressed in the cytoplasm (40). Both MDA5 and RIG-I recognize 
dsRNA and poly I:C. However, the two differ in the RNA patterns that they bind. RIG-I 
recognizes non-self 5´-triphosphorylated dsRNA and short poly I:C stretches (41-43) and its 
importance in the recognition on many different virus families, such as paramyxo-, flavi- and 
picorna-viruses has been demonstrated as well (44-46). MDA5 recognizes long dsRNA 
stretches and poly I:C (43, 47) and is important for the recognition of picornaviruses such as 
encephalomyocarditis virus (ECMV) and CVB (47-49). LGP2 also binds dsRNA but lacks 
the ability to signal downstream on its own. Instead, it seems to function by regulating RIG-I 
and MDA5 signaling (50, 51). The exact mechanism by which LGP2 regulates this pathway 
is, however, unknown.    
Viral sensing via these PRRs leads to the activation and induction of intracellular signaling 
pathways that promote an immune response. TLR3 signals via TIR-domain containing 
adapter-inducing IFNβ (TRIF) while TRL7-9 signal via myeloid differentiation factor 88 
(MyD88).  MDA5 and RIG-I signal via the common adaptor protein interferon-β promoter 
stimulator 1 (IPS1) (39, 52). Signaling via these adaptor proteins induces the activation and 
translocation of the transcription factors nuclear factor kappa light chain enhancer of 
activated B-cells (NF-κB) and IFN regulatory transcription factor 3 and 7 (IRF3 and IRF7) to 
the nucleus, which results in the subsequent production of proinflammatory cytokines and 
interferons (IFNs) (53). 
 
Figure 2: Model of signaling pathways involved in sensing CVBs 
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1.2.1.2 Interferons 
IFNs were discovered 60 years ago as proteins that can interfere with viral replication (54). 
Since then many studies have shown the importance of IFNs in protecting the host during 
early virus replication by inducing an antiviral state in neighboring cells. In addition, they 
have been shown to affect and shape the adaptive immune system by directing B cell and T 
cell responses (55-57). Today IFNs are divided into three groups based on their sequence 
homology. Type I IFNs consist of several isoforms of IFNα and one single isoform of IFNβ, 
as well as a number of additional subgroups whose functions in viral infection are less clear.  
Most cells can produce type I IFNs in response to viral infection which provide protection 
against a number of viruses (58, 59). Type II IFNs consists of only one type of IFN, IFNγ. 
IFNγ is important in regulating the response of immune cells and is mainly produced by T 
cells and NK cells. It activates macrophages and upregulates major histocompatibility 
complex (MHC) class I and class II expression (60). The type III IFNs (IFNλ) consists of 
four different isoforms, IFNλ1 (IL-29), IFNλ2 (IL28a), IFNλ3 (IL-28b) and IFNλ4 (61-63). 
Type III IFNs are mainly produced by cells of epithelial origin but can also be produced by 
certain types of immune cells (64, 65). IFNλs have both similar functions and antiviral 
properties to those of IFNα and IFNβ. However, type I IFNs signal via the IFNα-receptor 
(IFNAR) which is expressed on all cells (66), while type III IFNs signal via the IFNλ-
receptor (IFNLR) the expression of which appears to be limited to cells of epithelial origin 
and specific immune cells (64, 67, 68). Thus, the antiviral effects of type III IFNs appear to 
have greater organ selectivity and seem to be important mainly in the promotion of antiviral 
effects at viral entry sites such as mucosal surfaces. Type III IFNs are important in protection 
against hepatitis C virus (HCV) and CVB in hepatic cell lines and human islets (69, 70). 
However, some differences in the responsiveness to IFNλ between human and mouse 
hepatocytes have been demonstrated (71). 
Once IFNs are produced they are secreted and bind to receptors on cell surfaces. This binding 
activates intracellular signaling pathways that lead to the upregulation and expression of 
many different IFN stimulated genes (ISGs) which in turn will promote the cell to enter an 
antiviral state (72). The exact mechanisms through which several of these ISGs provide 
protection against infection are unknown. However, the function of the 2´-5´-oligoadenylate 
synthase (OAS) pathway has been demonstrated. IFNs induce OAS upregulation which can 
bind dsRNA, resulting in the activation of Ribonuclease L (RNase L). Activated RNase L 
targets both viral and cellular ssRNA for degradation (73). Another ISG which is quickly 
upregulated after IFN stimulation is IRF7 which is briefly described in 1.2.1.1. IRF7 is 
needed for the production of IFNα and is stimulated by IFNβ production (74, 75).  
1.2.2 The adaptive immune system  
The main cells of the adaptive immune system are the B cells and T cells, which are involved 
in antibody production and direct cell mediated killing of infected cells. The adaptive 
immune response offers a much more specific recognition of antigens than the innate immune 
response due to the fact that each lymphocyte undergoes somatic rearrangement of the B cell 
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and T cell receptor (BCR and TCR respectively) (76). This creates a vast number of different 
receptors that are able to recognize distinct antigens rather than a group of patterns. As the 
adaptive immune response requires firstly that the antigen is recognized by the correct BCR 
or TCR, followed by the initiation of clonal expansion, it is activated more slowly than the 
innate immune response. However, the adaptive immune response is more efficient than the 
innate immune response when it comes to eliminating the pathogen. Adaptive immunity is 
also important for the production of long lasting memory cells, which are the basis for 
immunological memory and an important function of modern vaccines.  
1.2.2.1 T cells 
There are two main types of T cells, CD8+ and CD4+, which are usually referred to as 
cytotoxic T cells and T-helper cells, respectively. CD8+ T cells are important for cell-
mediated toxicity while CD4+ T cells are important for proper antibody responses. CD8+ T 
cells are activated by antigens presented on MHC class I molecules, which are expressed by 
all nucleated cells.  CD4+ T cells are activated by antigens presented on MHC class II which 
has a more restricted expression and is found on so called professional antigen presenting 
cells (APCs) like DCs, macrophages and B cells (77). Antigen presentation on MHC class I 
or MHC class II, in combination with the expression of co-stimulatory molecules, leads to T 
cell activation. Once activated, the cells undergo clonal expansion, thus generating a large 
number of cells with the same receptor specificity. Recognition of antigens on infected cells 
by activated CD8+ T cells induces the killing of the cell through the release of perforin and 
granzyme, which stimulates apoptosis and the fragmentation of the cellular and viral 
genomes. In addition, activated T cells also secrete cytokines that further stimulate the 
upregulation of MHC class I expression on cells, and the recruitment and activation of 
macrophages. Activated CD4+ T cells help to modify the response of other immune cells and 
can induce upregulation of co-stimulatory molecules to further activate CD8+ cells. More 
importantly, the interaction between the TCR on activated CD4+ T cells with antigens 
presented on B cells, activates B cell proliferation and the production of antibodies and 
induces antibody class switch (77). 
1.2.2.2 B cells 
The main function of B cells is to produce antibodies in response to pathogens. B cells can be 
activated in a T cell independent (TI) or T cell dependent (TD) manner (78, 79). Activation 
of B cells without T cell help is thought to occur via the crosslinking of BCR upon encounter 
with antigen. This activation mainly produces antibodies of the IgM type and does not result 
in the induction of long-lived memory B cells. TD activation requires the interaction of a B 
cell with TCR. This interaction will also promote CD40-CD40L interactions, which induce 
antibody class switching, and thus modify the effector function of the antibody (80). There 
are five different classes of antibodies, IgA, IgD, IgE, IgM, and IgG. IgM and IgD are the 
earliest antibodies expressed after infection, although IgG is the most predominant form. The 
antibodies aid in clearing the infection by promoting phagocytosis, antibody-dependent 
cellular cytotoxicity, neutralization of the pathogen and complement mediated killing (81). 
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1.2.3 Viral immune evasion strategies  
Given the importance that the immune system has in preventing viral replication and spread, 
it is not surprising that several pathogens have developed mechanisms to inhibit activation of 
the immune response and to avoid recognition by the immune system. As described in 
1.1.1.1, CVBs target several cellular proteins to promote viral replication. In the same way 
many viruses can also target proteins to prevent their recognition by the immune system. 
Several studies have shown that viruses within the EV genus can target a number of proteins 
found in the IFN pathway (82). For example, both 2Apro and 3Cpro can inhibit the induction of 
both type I and type III IFNs by directly targeting IPS1 and TRIF, and thus inhibiting 
MDA5/RIG-I and TRL3 signaling in infected cells (83, 84). In addition, 3A has been shown 
to inhibit the secretion of cellular proteins and cytokines to reduce immune responses (85, 
86). This viral protein also mediates MHC class I down-regulation (87) thereby escaping 
recognition of T cells and T cell mediated cell death. 
1.3 TYPE 1 DIABETES 
Until the discovery of insulin in early 1920s, type 1 diabetes (T1D) was inevitably fatal. T1D 
results from an inability to properly regulate blood glucose levels due to a lack of the insulin 
producing beta cells. Insulin is a hormone that is needed for the upregulation of glucose 
transporters primarily on muscle cells and adipose tissue, which mediates the uptake of 
glucose from the bloodstream after food intake. T1D is the most common chronic disease in 
children and disease onset peaks between 5-7 years of age (88). The incidence of T1D in 
different countries varies drastically with 0.1 in 100 000 cases in low incidence countries 
such as Venezuela and up to 60 in 100 000 cases in high incidence countries like Finland (89, 
90). Patients with T1D require lifelong supplementation of exogenous insulin. Even though 
the treatment for T1D has long been known and practiced, the cause(s) of T1D development 
is/are yet to be understood.  
1.3.1 Autoimmunity 
It has long been suggested that the selective loss of beta cells in T1D is mediated by an 
autoimmune attack (91). This is supported by observations showing that over 90% of patients 
with T1D have autoantibodies to beta cell antigens such as glutamate decarboxylase (GAD), 
insulinoma-associated protein 2 (IA-2), zink transporter 8 (ZnT8) and insulin (92). Indeed, 
detection of two or more autoantibodies in serum is associated with a marked increase in the 
risk of developing T1D and the appearance of autoantibodies usually precedes T1D onset by 
months up to several years (93-95).  Furthermore, studies have shown that many islets from 
T1D patients are insulitic, which is usually defined by the presence of a lymphocytic 
infiltration of the islets. However, the criteria for diagnosing insulitis in humans has been 
debated lately, and when comparing human insulitis to that observed in the Non Obese 
Diabetic (NOD) mouse, a model for autoimmune T1D where islets are heavily infiltrated by 
autoimmune cells, the insulitis observed in humans is usually very mild (96). The matter is 
further complicated by studies showing that different islets from the same patient may or may 
not be insulitic (97). Still, if autoantibodies play a pathogenic role in T1D or whether they 
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result from ongoing beta cell destruction is not known. A study looking at pancreatic tissue 
from organ donors which were positive for one to four autoantibodies, showed that insulitis 
was detected in less than 10% of the islets in two out of three subjects which had at least three 
autoantibodies, but not in the other autoantibody positive subjects. However, none of the 
subjects in the study showed a decrease in beta cell mass (98).   
1.3.2 Environmental factors in T1D 
During recent years there has been a rapid increase in T1D incidence with the most dramatic 
rise seen in children under the age of 5 (88, 89). This escalation seems to occur in individuals 
carrying genes that were previously deemed to confer a low risk for T1D development. In 
fact, 85% of new T1D cases have no history of T1D in the family (99). The rapid increase in 
T1D suggests that there might be an augmented role for environmental factors in T1D 
development. Some environmental factors that have been suggested to regulate susceptibility 
to T1D include dietary factors (100-102), microbiotic alterations in the intestine (103, 104) 
and viral infections (11, 105, 106).  
Many studies have suggested infections with EVs are a potential trigger for T1D. It was 
already proposed in 1969 that CVBs could be involved in T1D development when Gamle et 
al published that antibodies to CVBs were found to be more frequent in newly diagnosed 
T1D patients compared to controls (107). This hypothesis was further supported in 1979 
when Yoon et al isolated CVB4 from a diabetic boy, which in turn could induce diabetes in 
mice (108). Since then many studies have tried to prove (or disprove) the role of virus 
infections in T1D etiology. Indeed, many studies have found EV RNA in blood samples, as 
well as the presence of EV viral protein 1 (VP-1) in pancreatic and intestinal biopsies, to be 
more frequent in T1D patients compared to controls (109-115). However, not all studies have 
been able to confirm the finding that EVs are present in the intestine of patients with T1D 
(116). A potential disadvantage with the studies that have looked at viral protein in the 
pancreas is that many of them have been conducted with pancreatic biopsies taken during 
autopsies, some of which were collected several years after T1D diagnosis. These may not 
necessarily be representative of what happens at disease onset. However, a novel study 
recently collected biopsies from six living T1D patients at time of diagnosis (117). The study 
showed that all patients were positive for EV in the pancreas at T1D onset. In four out of 
these six patients, they were also able to retrieve a virus sequence that corresponded to EVs 
(115).  
How EVs could contribute to T1D is still under speculation. A Finnish study recently 
associated CVB1 infections with the development of beta cell autoimmunity in children 
(118). Also, viral infections have previously been shown to cause autoimmune diseases and 
the proposed EV involvement in T1D shares many similarities with chronic myocarditis and 
dilated cardiomyopathy, where autoimmunity is associated with EV infection (119-123). EV-
induced myocarditis appear to be caused by a persistent, low grade viral infection of the heart 
in which the virus mutates to create a 5´terminally deleted virus (124, 125). Indeed, EV have 
been demonstrated to have a tropism for beta cells (126). In addition, EVs seem to have the 
  9 
ability to cause a persistent low grade infection in human pancreatic islets in vitro (127, 128). 
The finding that only very few cells are VP1 positive in islets from T1D patients further 
supports the theory that the virus is causing a low grade and possibly persistent infection 
(112, 115). As several recent studies have shown that many insulin positive cells remain in 
T1D individuals, with sometimes as much as 60% of the beta cell mass remaining (129), it is 
also possible that a low grade infection persists in insulin positive cells and causes beta cell 
dysfunction. Indeed CVB causes beta cell dysfunction when infected with EVs in vitro (111, 
130). In addition, insulin positive islets isolated from T1D donors that stained positive for 
VP-1 showed impaired insulin release upon glucose stimulation, suggesting that EVs also 
cause beta cell dysfunction after infection in vivo (111, 131). However, if viruses are 
involved in T1D development and through which mechanisms they may contribute to disease 
remains unclear.  
1.3.3 The islets of Langerhans 
The hormone insulin is produced by the beta cell which reside in the islets of Langerhans 
located within the pancreas. Islets of Langerhans are clusters of endocrine cells mainly 
comprising alpha cells, beta cells and delta cells (132). The beta cell is the most abundant cell 
type and secretes insulin in response to elevated levels of glucose in the blood, for example 
after eating a meal, to decrease blood glucose concentrations. In contrast, alpha cells produce 
glucagon which increases blood glucose concentrations. To aid these functions, the islets of 
Langerhans are highly vascularized with thin blood vessels and even though they only 
constitutes for 1-2% of the total pancreatic mass, they receive 5-10% of the pancreatic blood 
flow in order to properly regulate blood glucose levels and maintain homeostasis (133). 
1.3.3.1 Regulation of insulin secretion 
Glucose is taken up from the blood by sensitive glucose transporters (GLUT1 and GLUT2), 
which are expressed in the beta cells in humans and rodents, respectively, (134, 135). The 
internalized glucose is used to generate ATP which triggers the depolarization of the cell by 
closing ATP sensitive potassium (K) channels. This in turn results in the opening of voltage 
gated calcium (Ca2+) channels. Beta cells express many different types of Ca2+ channels; L-
type, N-type, P/Q-type, R-type and T-type which are activated at different voltages to 
regulate Ca2+ influx (136). The increased levels of intracellular Ca2+ will result in the fusion 
of the insulin vesicle with the cell membrane, a process known as exocytosis, and insulin will 
be released into the bloodstream and transported to target organs like the muscles and liver.  
Insulin is released in a biphasic manner (137). The first phase is induced very rapidly, as 
quick as 1 minute after a rise in blood glucose levels, and lasts for around 5-10 minutes. The 
second phase is activated after 10 minutes and can be sustained for hours until 
normoglycemia is restored. The nature of this biphasic pattern is thought to be a result of two 
different pools of insulin granules namely the readily releasable pool (RRP) and the reserve 
pool (RP) (138, 139) that are present in each individual beta cell. Around 1-5% of insulin 
granules belong to the RRP which are already docked to the plasma membrane and primed 
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making them available for the immediate release of insulin upon an increase in intracellular 
Ca2+ levels.  The RP requires mobilization of insulin granules to the plasma membrane and 
priming before they can be released (140).  
 
Figure 3: Simplified schematic showing signaling pathways involved in insulin secretion 
1.4 CYSTIC FIBROSIS 
Cystic fibrosis (CF) is the most common life shortening recessive genetic disorder in 
Caucasians with an incidence ranging from 1:1300 in Ireland to 1:25000 in Finland (141). 
Symptoms of CF in children have been described for many hundreds of years. However the 
cause for the disease was not known until the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene was discovered in 1989 (142, 143). CF is a multi-organ disease. One 
of its most prominent features is the abnormal water and ion transport in cells lining the 
respiratory tract which results in the accumulation of up in the lungs (144). The inability to 
properly clear this thick mucus from the lungs is thought to be the underlying cause of 
decreased bacterial clearance and chronic respiratory infections, eventually leading to 
respiratory failure and early mortality. Before the discovery of antibiotics Staphylococcus 
aureus was the main cause for early mortality and the majority of children died before 5 years 
of age (145, 146). Today, due to improved treatments, life expectancy has increased to over 
40 years (147). 
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Figure 4: Impact of CFTR expression in lung epithelial cells. In the lung, CFTR is 
expressed on the apical side of epithelial cells and it is important for controlling electrolyte 
balance. In CF patients, the defective transport of chloride ions causes the accumulation of 
chloride inside the cells and increased influx of sodium and water. This results in dry, viscous 
mucus and decreased cilia movement making the environment favorable for bacterial 
colonization.  
1.4.1 CFTR 
CFTR encodes a chloride channel which is located in the cellular membrane and is needed for 
maintaining the properly balance of electrolytes (142, 143). Several hundred different 
mutations in CFTR contributing to CF have been identified. The mutations can be divided 
into six different classes depending on how the mutation affects the protein (148). In class I 
and class II there is a complete lack of protein synthesis (class I) or defective protein 
processing (class II), whereas class III-VI mutations rather affect the function or the 
expression of the chloride channel in the cell membrane. The most common mutation found 
in humans is caused by a deletion of a phenylalanine residue at position 508 (F508del) that 
results in the degradation of the protein before the protein reaches the cell surface. F508del is 
a class II mutation and affects 70-88% of patients with CF (149).  
1.4.1.1 CFTR expression and function 
CFTR is expressed in many organs of epithelial origin such as the lung, pancreas, intestine 
and reproductive organs and is necessary for their normal function (150). The defective ion 
secretion caused by dysfunctional CFTR does not just cause viscous mucus in the lungs but 
also leads to the obstruction of pancreatic ducts and vas deferens resulting in pancreatic 
insufficiency and the need for pancreatic supplements, as well as infertility (151, 152). CF 
also gives rise to meconium ileus bowel obstruction which affects 10% of neonates with CF 
(153). In addition to its importance in regulating electrolyte balance, CFTR has also have 
been shown to regulate the function of other proteins and ion channels such as Syntaxin 1a 
(154), ORCC (155, 156) and Anoctamin 1 (ANO1) (157). More recent studies have also 
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noted the importance of CFTR in the immune system and several studies have suggested that 
immune cells express CFTR (158-162), but little is known of the exact function of CFTR in 
different lymphocyte populations. Today novel treatments for CF are being developed in 
form of correctors, such as Lumacaftor, to correct CFTR folding and increase protein stability 
and potentiators, such as Ivacaftor, which potentiates channel opening probability and aims to 
restoring CFTR function (163, 164).  
1.4.2 Impaired immune functions in CF 
In addition to the decreased mucus clearance in the CF lung which results in bacterial 
infections, CF patients appear seem to be more prone to severe respiratory viral infections, 
which are prolonged in duration (165), suggesting that CFTR affects the immune response. 
Of note, these viral infections also seem to predispose the CF lung to bacterial colonization 
(165-169), thus contributing to pulmonary exacerbations and morbidity (165, 170). An 
overall dysfunctional antimicrobial immune response has been observed in CF lung epithelial 
cells with lower nitric oxide synthase 2 (NOS2) and OAS production leading to impaired 
activation of IRF1 (171). In addition, lower levels of TLR4 have been observed (172, 173). A 
dysregulated immune response has also been documented in the intestine and pancreas of CF 
patients (174-176).  
Impaired function of immune cells in CF has also been observed. Lymphocytes express a 
number of chloride channels which are needed for the secretion of cytokines and regulation 
of immune responses. Since CFTR is expressed in lymphocytes, it would not be surprising if 
it affected their function. Indeed, CF patients have a skewed Th2 response and defective T 
helper cell function (177, 178) and this is postulated to be due to an intrinsic defect of the T 
cell population (179). In addition, DCs have been shown to have an impaired function due to 
low levels of sphingosine-1-phosphate (S1P) and machophagues have a decreased phagocytic 
capabilities (162, 180, 181).  
Although many studies show that CF is associated with a diminished immune function, the 
CF lung displays a proinflammatory phenotype (175, 182, 183). This may, in part, be due to 
the constant stimuli of pathogens in the lung but may also be caused by the defective cells 
themselves. For example, even though neutrophils were shown to be functionally abnormal in 
protecting against pathogens, neutrophil airway mediated inflammation is dominating lung 
disease in CF (184-186). Thus the defects within the leukocyte population could promote the 
inflammatory milieu in the lung and contribute to lung damage. 
1.4.3 The CFTRtm1EUR mouse model 
Several models have been developed to study the effects of CF mutations in vivo. Among the 
more recent models are ferrets and pigs, which seems to resemble the human disease in many 
aspects (187-189). However, the mouse has been by far the most used model to study 
different CF mutations as they are relatively easy to manipulate. The CFTRtm1EUR mouse 
model carries the F508del mutation and thus mimics the most common form of CF in humans 
(190). The mouse has a similar phenotype to human CF with electrophysiological 
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abnormalities of the gastrointestinal tract and failure to reproduce (190). However, the most 
common feature of human CF, namely mucus accumulation and progressive inflammation in 
lung, are not observed in the CFTRtm1EUR mouse. Still, when challenging these mice with 
environmental factors such as respiratory pathogens, the pathology was more severe 
compared to control littermates (191) suggesting that, as in humans, environmental exposure 
can worsen CF pathology.
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2 AIMS OF THE THESIS 
The overall aim of this thesis was to increase our knowledge of innate and adaptive immune 
response mechanisms to CVB infections. In addition, we aimed at determining the role of 
CVB encoded proteins in evading immune response mechanisms and causing beta cell 
dysfunction. 
 
Specific aims: 
• To assess whether type III IFNs are induced by CVB infection in primary human 
hepatocytes and regulate permisiveness to CVB infection (Paper I) 
 
• To study if CVB has evolved strategies to inhibit type III IFN production by infected 
cells (Paper II) 
 
• To investigate the mechansims of CVB-mediated inhibition of insulin scretion from 
infected cells (Paper III) 
 
• To study how the F508del mutation in CFTR affect the immune response to a 
common EV infection (Paper IV) 
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3 MATERIAL AND METHODS 
Many different experimental techniques were used when performing the experiments 
included in Papers I-IV. In this section I have chosen to discuss some of the most important 
methods that were employed.  
3.1 VIRUS STRAINS 
In all of the papers included in this thesis (Paper I-IV), I have used the CVB3 Nancy strain, 
and on some occasions the CVB4 E2 strain (in Paper III). These two CVB strains have been 
well characterized and are used widely throughout the field. The strains were propagated in 
HeLa cells and viral supernatants were centrifuged to remove cellular debris. In the 
functional studies that I performed in Paper III, the virus stocks were purified. Virus 
purification was performed by ultracentrifugation of virus suspension through a 40% sucrose 
cushion. This was important so as to avoid contamination from HeLa the cells that died 
during virus propagation and may release cytokines and other factors into the virus 
suspension that might affect cell function during infection.  
3.2 CELL LINES 
Different cell lines were employed in the experiments performed in Papers I-III. In Paper I 
we utilized HepG2 and Huh7.5 cells which are both derived from human liver. We used these 
cells as models to investigate whether type III IFNs protect against CVB infections prior to 
the experiments that were performed with primary human hepatocytes. In Paper II, HeLa 
cells were used as we know from previous experiments that they are susceptible to CVB 
infection and they mount an intact type III IFNs response upon stimulation with poly I:C. In 
Paper III, experiments were carried out with the INS1-832/13 cell line (192). This cell line is 
derived from the INS1 cell line and have been stably transfected with the human proinsulin 
gene. INS1-832/13 cells have a stable insulin responsiveness to glucose stimulation, thus 
making their use favorable when studying the effect of insulin secretion over other 
insulinoma cell lines such as RIN cells, which are not glucose-responsive (193). A 
disadvantage with the INS1-832/13 cell line is that it is derived from rat and not from human. 
Differences in the types of Ca2+ channels which are important for triggering exocytosis has 
been documented between human and mouse beta cells, as well as in INS1-832/13 cells (194-
197). This is important to remember when interpreting the results. 
3.3 PRIMARY HUMAN CELLS 
The use of primary human cells may sometimes be a better option when performing 
experiments. However, access to human material and ethical implications make these 
experiments more challenging. Additionally, humans are not genetically uniform and 
depending on the hypothesis you want to address, the results can vary greatly due to the genes 
present, which may significantly alter your results. However, if your goal is to study how 
specific genetic variations in the human population affect experimental outcomes, then the 
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use of primary human cells is preferable to the use of cell lines. In Paper I, we used primary 
human hepatocytes for our experiments and in Paper III we used isolated human islets.  
3.4 ANIMALS 
When studying complex immune pathways where multiple cell types depend on one another 
for accurate input signals and synergy, the use of cell lines is not possible. As such, animal 
models are utilized to study these more intricate interactions. It is, however, very important to 
adhere to strict ethical guidelines when performing animal experiments to minimize 
suffering. Mice in particular are attractive models due to the ease with which they can be 
genetically manipulated and their fast reproductive capacity. Today, there are many different 
mouse models available and they provide useful tools for studying complex diseases. In 
Paper IV I have used the CFTRtm1EUR  mouse model which carries the most common 
mutation resulting in CF in humans, F508del (190). By using the CFTRtm1EUR mouse I hoped 
to gain insight into what function CFTR have in immune cell populations by studying the 
immune response to a common EV infection. All experiments performed in this thesis were 
carried out according to Swedish law.  
3.5 HORMONE SECRETION 
Glucose stimulated insulin secretion assays was performed with human islets and INS1-
832/13 cells in Paper III. Important factors to consider when using isolated islets for 
functional experiments include that the isolation procedure and transport of the islets may 
affect their viability and ability to secrete insulin. In addition, upon arrival at the Karolinska 
Institutet, islets were kept in culture for 2-9 days to recover before the start of experiments. 
Islets are normally highly vascularized and without this system ex vivo, the lack of oxygen 
transport to the center of the clusters may cause hypoxia. Thus, I included only islets that 
maintained function and could respond to glucose stimulation in my experiments when 
studying insulin secretion (as statistically determined by T test).  
With the INS1-832/13 cells I used the human Growth Hormone (hGH) assay to measure 
hormone release after glucose stimulation. This was due to the fact that transfection 
efficiency of INS1-832/13 cells was low (around 10-15%). As a result of this, when 
performing measurements of insulin release, 85% of the insulin released would originate 
from cells that were not expressing the viral proteins. To circumvent this problem, viral 
proteins, or control plasmid, were co-transfected with hGH plasmid. Since hGH is secreted 
by the same vesicles as insulin, hGH will be released from transfected cells upon glucose 
stimulation allowing us to study hormone secretion in only the cells overexpressing viral 
proteins with an hGH ELISA (Figure 5). 
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Figure 5: Diagram illustrating the hGH assay. Due to low transfection efficiency, hGH 
was used to measure hormone release after glucose stimulation in transfected INS1-832/13 
cells. Cells were co-transfected with hGH (grey) and control plasmid (green) or plasmids 
encoding the different viral proteins 2Apro, 3A or 3Cpro (red). hGH is loaded into the same 
vesicles as insulin and co-secreted with insulin upon glucose challenge. The release of hGH 
from transfected cells was measured with ELISA.   
3.6 PATCH CLAMP 
To measure Ca2+ currents and study the exocytosis of insulin granules in INS1-832/13 cells, I 
performed patch clamp studies in Paper III using the standard whole cell configuration. This 
is achieved by creating a tight seal between the pipette and the membrane wall of the cell and 
then applying negative pressure to remove the membrane patch within the pipette. Removal 
of the membrane patch allows replacement of the cytosol with the pipette solution, giving 
total control over the intracellular milieu. In addition, it allowed me to add active 2Apro in the 
intracellular solution of the pipette before applying my stimulation protocols. For studies 
looking at the effects of 3A and 3Cpro, cells were transfected the day before performing 
experiments. Since 3A and 3Cpro transfected cells could be identified by GFP expression, 
only GFP positive cells were chosen for patch clamp studies. To study the function of Ca2+ 
channels, a protocol in which the cells were depolarized from -70 to voltages between -50mV 
to +50mV for 50 ms was used and Ca2+ currents were recorded. To study exocytosis, an 
increase in cell membrane capacitance was measured. Exocytosis was triggered by a train of 
ten 500 ms depolarizations from -70 to 0 mV. During exocytosis, insulin granules fuse with 
the membrane of the cell and increase the cell surface area. Membrane capacitance is 
calculated using the formula C=(ε*A)/d. Since biological membranes have a specific 
capacitance of 9 fF/µm2 (ε) and d is the distance between the two layers of phospholipids 
(both of which are constants), the measured changes in membrane capacitance is proportional 
to the increase in cell area (A) and reflects the fusion of insulin granules.  
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
Infections caused by CVBs are common in young children. In a proportion of infected 
children, CVBs cause hepatitis, which in many cases is fatal (198, 199). Proper regulation 
and induction of immune response mechanisms are crucial for controlling and inhibiting early 
virus replication. Several studies have shown the importance of type I IFNs in preventing 
early CVB replication and spread (200, 201). However, the ability of the type III IFNs to 
prevent CVB replication was, until recently, relatively undiscovered. CVBs have previously 
been shown to induce type III IFN expression in primary human islets after infection (70). 
However, whether the type III IFNs are produced by human hepatocytes in response to CVB 
infection had not been investigated. In Paper I we studied whether the type III IFNs are 
induced in human hepatocytes upon CVB infection and if type III IFN protects primary 
human hepatocytes from CVB infection.  
We started by showing that primary human hepatocytes are susceptible to CVB infection and 
that titers of replicating virus increased over time (Paper I, Figure 1A). In addition, these 
infected hepatocytes seemed to respond to CVB infection by up regulating mRNA expression 
levels of IFNλ1 and IFNλ2 (Paper I, Figure 1B). Consistent with results seen in previous 
studies, we confirmed that human hepatocytes express both subunits of IFNLR (Paper I, 
Figure S1) and that they respond to type III IFN treatment by up regulating ISG expression 
(Paper I, Figure 3A). More importantly, pretreatment with IFNλ1 or IFNλ2 protected human 
hepatocytes from CVB replication (Paper I, Figure 3B). Thus, we showed that human 
hepatocytes respond to CVB infection by producing IFNλ1  and IFNλ2 and that type III IFNs 
promote the protection of primary human hepatocytes from CVB infection.  
This article was published before the approved use many new antiviral therapies such as 
Harvoni in treating chronic HCV infections. Until then, pegylated IFNλ had been considered 
as a new potential treatment in place of pegylated IFNα for chronically infected HCV 
patients as it caused less severe side effects, due to the limited expression of IFNLR (202, 
203). As of today, there is no specific treatment for severe hepatic infections caused by 
CVBs, only in life threatening conditions imunogloubolins or pleconaril can be administrated 
(204, 205). Few studies have looked at the effects of pegylated IFNλ on acute HCV 
infections in humans, since they are usually very mild and not diagnosed until the chronic 
phase (206). However, the use of pegylated IFNλ in treating acute CVB infections, which 
display more severe symptoms such as hepatitis, could be of interest to study.  
A limitation with our study is that we did not investigate the induction of IFNλ3. In addition, 
very little was known about the newly discovered IFNλ4 gene at the time of publication. This 
could be of interest to investigate in the future since studies exist showing that single 
nucleotide polymorphisms (SNPs) in the IFNλ3 and IFNλ4 genes appear to determine 
whether patients are able to spontaneously clear HCV infection or if they progress to chronic 
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disease (207) as well as determining the effectiveness of IFN treatment (206). If SNPs in 
IFNλ3 and IFNλ4 would render children more prone to developing hepatitis after CVB 
infection and whether, as a result, IFN treatment would be less effective in these individuals 
is not known, but they are important factors to consider.  
To summarize, in Paper I we show that type III IFNs protect human hepatocytes from CVB 
infection. 
4.2 PAPER II 
As IFNs are important for inhibiting early viral replication, it is not surprising that many 
viruses have evolved different mechanisms to interfere with IFN production and downstream 
functions (82). Studies have shown that both 2Apro and 3Cpro of CVBs have the ability to 
block type I IFN production (83, 84). Whether CVBs have evolved similar mechanisms to 
inhibit the induction of type III IFNs had not been studied. However, given the importance of 
type III IFNs in protecting against CVB infection in other cells types ((70) and shown in 
Paper I), we hypothesized that CVBs have also evolved mechanisms to inhibit their 
production. In Paper II we set out to determine if CVBs inhibit type III IFN induction and if 
so, by what mechanism(s).  
In this study we used HeLa cells, which are readily infected by CVBs, as a model system. 
Since CVBs are recognized by RIG-I, MDA5 and TRL3 (33, 46, 48) we wanted to look at 
the inhibitory effect of CVBs on both the RLR and TLR3 pathways. Thus, poly I:C was 
administered either exogenously, to study the type III IFN induction by TLR3 (34), or via 
transfection to look at type III IFN induction by RIG-I and MDA5 (208, 209). We started by 
confirming that HeLa cells up regulate IFNλ1 and IFNλ2 expression when exposed to poly 
I:C, via both the RLR and TLR3 pathways (Paper II, Figure 1A). In stark contrast, CVB3 
was a poor inducer of type III IFNs (Paper II, Figure 1A). In addition, we showed that HeLa 
cells infected with CVB do not up regulate type III IFN production after poly I:C stimulation 
(Paper II, Figure 2A), suggesting that CVB is able to inhibit the pathways through which 
poly I:C induces type III IFN production.  
Next, we wanted to study which proteins in the PRR signaling pathways are targeted by the 
virus. Induction of type III IFNs is dependent on activation of the transcription factor IRF3. 
IRF3 activation occurs after hyperphosphorylation of the protein, resulting in dimerization 
and translocation to the nucleus (210, 211). When comparing the phosphorylation pattern of 
poly I:C stimulated cells to that of CVB infected cells, we observed that no 
hyperphosphorylation of the IRF3 protein was observed in CVB infected cells (Paper II, 
Figure 3A). The IRF3 phosphorylation pattern was in agreement with the results published by 
Feng et al (84). This led us to believe that signaling molecules upstream of IRF3 were 
affected in CVB infected cells 
Two important proteins upstream of IRF3 are the adaptor proteins IPS1 and TRIF, which 
mediate signaling from the PRRs MDA5/RIG-I and TLR3, respectively. Indeed, we 
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demonstrated that CVB infection decreased the expression of both IPS1 and TRIF (Paper II, 
Figure 4). In addition, the decreased expression of both full-length proteins correlated with 
the appearance of one or several cleavage products (Paper II, Figure 4) suggesting that 
CVBs inhibit type III IFN signaling pathways by cleaving these adaptor proteins.  
Many EVs have been shown to induce apoptosis in infected cells resulting in caspase 
activation and degradation of several cellular proteins, including IPS1 (212), by the 
proteasome. Thus, to exclude the possibility that the observed cleavage of IPS1 and TRIF 
was a result of CVB induced apoptosis, we infected cells in the presence of caspase and 
proteasome inhibitors. This established that the expression of both IPS1 and TRIF still 
decreased in infected cells even when apoptosis was inhibited (Paper II, Figure 5) suggesting 
that the virus itself is responsible for mediating the cleavage of these cellular proteins.  
CVB encodes two proteases, 2Apro and 3Cpro, which are capable of mediating cleavage of 
cellular proteins eg in (17, 20, 213). To study their respective roles in inhibiting type III IFN 
production, HeLa cells were transfected with the separate viral proteases before stimulation 
with poly I:C. We found that overexpression of 2Apro, but not 3Cpro, significantly decreased 
poly I:C induced IFNλ1 and IFNλ2 expression (Paper II, Figure 6). In addition, when 
treating cell lysate with active 2Apro we observed the same cleavage pattern of IPS1 and TRIF 
as in infected cells (Paper II, Figure 7).  
In Paper II we show that 2Apro is inhibiting type III IFN production. Even though the actual 
cleavage sites of IPS1 and TRIF that are targeted by 2Apro were not investigated, it seemed 
likely that the protein cleavage was due to the proteolytic activity of the viral protease. This 
was further supported by the fact that we could exclude a role of cellular proteases and 
apoptosis in our experiments as the source responsible for cleaving IPS1 and TRIF. In 
addition, the same cleavage pattern was observed in CVB infected and 2Apro treated cells and 
cleavage products of both IPS1 and TRIF were dependent on the concentration of active 
2Apro (Paper II, Figure 7).  
In contrast to a study published in 2011 where it was concluded that type I IFN production is 
inhibited by 3Cpro mediated cleavage of IPS1 and TRIF (83), we did not see any effects of by 
3Cpro in our experiments. Our results were in agreement with those published in 2014 by 
Feng et al, showing that IPS1 and MDA5 are targeted by 2Apro in CVB infected cells (84). In 
addition to their findings, we also showed that TRIF was targeted by 2Apro. One explanation 
for these different findings made by Mukherjee et al and us, could be the different time points 
used to look at the effect of overexpressed 2Apro and 3Cpro. Since we observed that 2Apro 
rapidly induced toxic effects in our transfected HeLa cells (Figure 6) we looked at the protein 
expression and cleavage of IPS1 and TRIF at much earlier time points than in the study 
published by Mukherjee et al. It may be that with longer overexpression studies, we might 
have observed some additional effects with 3Cpro, but at least at early time points after 
infection, 2Apro seems to play the predominant role in cleaving IPS1 and TRIF. In fact, 
overexpressing 2Apro alone did not inhibit IFNλ expression to the same extent as that seen in 
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CVB infected cells, suggesting that there may still be additional effects by 2Apro, or other 
viral proteins, at later time points than those chosen for our experiments. Indeed, when 
looking at decreased protein expression in infected cells, TRIF seemed to be cleaved earlier 
than IPS1. In the paper by Feng et al, they also show an effect of 3Cpro in cleaving RIG-I, 
although this effect was not observed until 9h after infection. We also observed a decreased 
protein expression of both MDA5 and RIG-I in our studies, but these occurred after 4-6h of 
infection at the end of the viral replication cycle. Taken together, this suggests that proteins 
present in the type III IFN pathway are cleaved at different time points after infection by 
2Apro and 3Cpro. 
Figure 6: 2Apro affects viability in transfected HeLa cells. Transfection with 2Apro induces 
cell death in HeLa cells 24h after transfection as compared to the control plasmid, pCMS, or 
3Cpro. 
In addition to directly cleaving proteins within the IFN pathway, both proteases have also 
been shown to inhibit transcription and translation in infected cells (18, 214, 215). The 
cleavage of eIF4G and inhibition of cellular protein production seemed to be an early event in 
the virus life cycle and complete cleavage of the protein occurred before 2h (unpublished 
data). Thus the decrease of full-length proteins could also, to some extent, be mediated by 
decreased protein synthesis in the cell. The effect of decreased protein expression due to 
translation shut down is hard to study separately as this effect is also mediated by 2Apro and 
3Cpro. Of course, the almost complete and very efficient blockage of type III IFNs in infected 
cells could be explained by a combination of effects by both of the viral proteases on protein 
production as well as direct cleavage of target proteins to maximally inhibit the type III IFN 
response.  
Only a few studies have looked into the mechanism by which different viruses inhibit type III 
IFNs. However, at mucosal surfaces, which are the primary infection route of CVBs, very 
little IFNAR is expressed and the protective effects in mucosal cells seem to be mainly 
mediated by type III IFNs (216). Thus, inhibition of type III IFNs may help the virus to 
establish infection in the intestinal mucosa and spread to cause systemic infections.  
In conclusion, we show in Paper II that CVB inhibits the type III IFNs by targeting proteins 
of both the RLR and TLR3 pathways though 2Apro mediated cleavage. 
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4.3 PAPER III 
It has been suggested that infections caused by EVs are involved in the etiology of T1D. 
Indeed, several studies have reported the presence of EV protein within islets of T1D patients 
(110, 112, 115). The fact that only very few cells are positive for VP1 suggests that there 
may be a low grade and possibly persistent infection within the islets. Previous studies have 
shown that CVBs are able to cause beta cell dysfunction after infection in vitro (111, 130). 
However, the mechanism by which CVBs cause beta cell dysfunction is not known. CVBs 
encode several viral proteins that have been shown to interfere with cellular functions and 
signaling pathways e.g. ((217) and shown in Paper II). Therefore, we hypothesized that 
virus-encoded proteins cause the defective insulin secretion in infected islets. Thus, in Paper 
III we wanted to study the individual effects of viral proteins on insulin secretion to identify 
the mechanisms through which CVBs cause beta cell dysfunction.  
We started by confirming the findings that infected human islets have a decreased ability to 
secrete insulin in response to glucose. Indeed, both CVB3 and CVB4 infected islets had a 
decreased insulin release compared to uninfected control islets from the same donor (Paper 
III, Figure 1B). As CVBs are able to inhibit transcription and translation in infected cells, we 
wanted to exclude the possibility that the decreased insulin secretion was due to differences 
in the expression levels of intracellular insulin in infected and control islets. Therefore, we 
looked at intracellular insulin protein and insulin mRNA expression levels in infected and 
control islets. While levels of intracellular insulin proteins did not differ, the expression of 
insulin mRNA was lower in infected islets (Paper III, Figure 1C-D). As insulin protein 
content was not decreased at the time of our experiment, the diminished release of insulin 
from infected islets was more likely due to mechanistical defects in beta cell function. 
However, if T1D is caused by a persistent rather than an acute infection, like the one we have 
studied here, then insulin protein expression may decline over time due to inhibited 
transcription of insulin RNA, which may further contribute to a decrease in insulin secretion.  
As access to human material is sparse and the islets consist of a mixture of endocrine cells we 
wanted to establish an infection model system in which we could perform mechanistic studies 
specifically in beta cells. By using the INS1-832/13 cell line, we confirmed our results seen 
with CVB infected islets (Paper III, Figure 2C-D) and showed that this is a valid model in 
which to study the effect of CVB induced inhibition on insulin secretion. In this cell system it 
was important to monitor viability during the experiments because infections with CVB have 
been shown to cause lysis of cells in vitro which would cause the unspecific release of insulin 
from lysed cells into the supernatant. However, at the terminal time point in our experiment, 
there were no obvious increases in cell death (Paper III, supplementary table 1). In addition, 
the majority of replicating virus was still inside the cells rather than in the supernatant, further 
supporting that the cells have not yet been lysed by the infection (Paper III, Figure 2A).  
Next, we wanted to study the effect of separate viral proteins on insulin secretion. The viral 
proteins 2Apro, 3A and 3Cpro have previously been shown to interfere with several cellular 
functions (17, 218). Thus, these proteins were chosen for overexpression studies in INS1-
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832/13 cells. Insulin secretion is a tightly regulated process that is dependent on many 
intracellular signaling steps, briefly described in 1.3.3.1. Before exocytosis can occur, Ca2+ 
must enter the cell to promote the fusion of insulin granules with the cellular membrane. 
Therefore, we performed patch clamp experiments to look at Ca2+ influx in INS1-832/13 cells 
treated with different viral proteins. Our result showed that 2Apro and 3Cpro inhibited Ca2+ 
influx while 3A did not (Paper III, Figure 4). However when looking at exocytosis in these 
cells all proteins were able to decrease the voltage stimulated release of insulin granules, with 
the most dramatic effect being on the RRP (Paper III, Figure 5). Beta cells express many 
different types of Ca2+ channels that are activated at different voltages to regulate exocytosis. 
Thus, it would be interesting in future studies to follow up on our findings and establish if the 
proteases target a specific channel and if so, how this inhibition is mediated. In contrast to the 
proteases, 3A inhibited exocytosis in a Ca2+ independent manner. 3A has previously been 
shown to inhibit protein secretion from other cell types by disrupting the of ER to Golgi 
transport (85). It is tempting to speculate that 3A might inhibit insulin secretion by the same 
mechanism, but this remains to be established.   
So far we had observed that CVB seems to have the ability to inhibit insulin secretion via 
different mechanisms, such as the inhibition of transcription, Ca2+ influx and voltage 
stimulated exocytosis. Next, we wanted to address the individual effects of 2Apro, 3A and 
3Cpro on glucose stimulated hormone release. By using the hGH, assay where hGH is loaded 
into the same vesicles as insulin, we were able to study hormone release specifically in 
transfected cells (as discussed section 3.5). These experiments showed that the viral proteins 
have very different effects on hGH expression and release (Paper III, Figure 6). Both 2Apro 
and 3Cpro seemed to be responsible for decreasing mRNA production in transfected cells 
(Paper III, Figure 6A) with 2Apro mediating a near to complete block. The decreased levels 
of hGH mRNA also probably explains why 2Apro and 3Cpro transfected cells also had lower 
or no expression of hGH protein (Paper III, Figure 6B). Interestingly, 3A increased the 
levels of hGH (Paper III, Figure 6B). When normalizing the levels of secreted protein to 
intracellular protein levels, it seemed like 3A has the most drastic effect on hormone secretion 
(Paper III, Figure 6C). However, 3Cpro appeared to increase basal levels of hormone release, 
indicating that beta cell function is also impaired in these cells. A disadvantage with this 
experiment, which demonstrated that 2Apro seemed to be the main protein responsible for 
decreasing mRNA levels, was that we could not study the effect of 2Apro on actual hGH 
release. One way to circumvent this problem and study the separate effect of 2Apro on 
hormone release could be to create an IRES construct in front of the hGH in the plasmid. 
Since IRES is normally used by the virus to promote viral replication in cells, even when 
cellular protein production in inhibited, this would allow hGH production in cells where 
protein translation is normally inhibited. It is important to note that in our patch clamp 
experiments, active 2Apro was administrated via the pipette directly in the intracellular 
solution for no more that three minutes. This supports the point that direct cleavage by 2Apro 
is responsible for inhibiting exocytosis in these experiments, rather than a decreasing in 
protein expression.  
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One limitation with our study is that we only choose to study the effect of three out of seven 
viral nonstructural CVB proteins, which have been shown to have an effect on cell function. 
Indeed, the 2B protein of poliovirus and CVB has also been shown to also inhibit protein 
secretion in cells (217, 219) suggesting that it also may have the ability to inhibit insulin 
secretion. Thus, we cannot exclude that additional viral proteins might contribute to beta cell 
dysfunction in infected islets.  
To summarize, in Paper III we have shown for the first time that separate viral proteins 
target different steps of the insulin secretion pathway resulting in beta cell dysfunction.  
4.4 PAPER IV 
CF is the most common life shortening disease in Caucasians. A large proportion of the 
mortality rates are due to chronic bacterial infections of the lung resulting in respiratory 
failure. Of note, studies have suggested that viral infections seem to predispose the CF lung to 
bacterial infections and contribute to early mortality (166, 167). In addition, a defective 
antiviral response in CF patients has been observed (171). EVs, such as rhinoviruses, are 
common virus infections that have been shown to contribute to pulmonary exacerbations in 
CF (165, 220). Thus in Paper IV we wanted to study the effect of the most common CF 
mutation and how it affects immune responses to CVB infection. 
We started by using an in vivo model for CF to study overall survival after CVB infection. To 
this end, we used the CFTRtm1EUR mouse, which carries the most common CF mutation found 
in humans, F508Del (190). Our results showed that mice carrying the F508del mutation had 
strikingly impaired survival after challenge with CVB compared to wild-type (wt) controls 
(Paper IV, Figure 1). When analyzing early viremia from infected animals, we found no 
difference when comparing the wt and CFTRtm1EUR mice (Paper IV, Figure 2A) suggesting 
that they had the same susceptibility to infection. However, viral replication in different 
organs from CFTRtm1EUR mice was higher at day 5 and day 7 post infection (Paper IV, 
Figure 2B and D). These findings suggest that the CFTRtm1EUR mice have an impaired ability 
to inhibit viral replication after infection.  
The immune system is divided into the innate and adaptive arms. IFNs are an important part 
of the innate immune response in the inhibition of early viral replication, and they also 
provide activating signals for the adaptive immune response (55-57). It has been shown that 
type I IFNs are essential for surviving EV infections, however type II IFNs are indispensible 
for survival (200, 201). Thus, we looked to see if there was a defective induction of type I 
and type III IFNs after stimulation with poly I:C in these mice. Although we did not observe 
any difference in tissue specific IFNβ and IFNλ production (Paper IV, supplementary figure 
2 and Figure 3C-D), the production of IFNα in serum from CFTRtm1EUR mice was 
significantly lower at 2h but not at 4h post injection (Paper IV, Figure 3B), suggesting that 
IFNα induction was delayed.  
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Since we did not observe any major differences in early viral replication between wt and 
CFTRtm1EUR mice this may indicate that the problem lies within the adaptive immune 
response. An important feature of the adaptive immune response is the production of 
neutralizing antibodies to the virus, which aid with the clearance of the infection. Indeed, 
when looking at the presence of virus specific IgM and IgG antibodies in serum from infected 
mice, we found that no CFTRtm1EUR mice had developed antibodies at day 5 post infection 
while more than half of the wt animals did have antibodies (Paper IV, Figure 4A). In 
addition, all wt mice had high levels of IgM and IgG antibodies at day 7 post infection while 
the levels in CFTRtm1EUR mice were significantly lower (Paper IV, Figure 4A). The levels of 
antibodies with the ability to neutralize the virus in mice followed the same pattern as the 
virus specific IgM and IgG antibody responses (Paper IV, Figure 4B-C). The importance of 
these neutralizing antibodies in protecting CF mice from a lethal infection was further 
demonstrated in an adoptive transfer experiment (Paper IV, Figure 5). To exclude the 
possibility that the lower production of antibodies was not due to major differences in 
immune cell populations, we analyzed the frequency of major immune cell subsets between 
wt and CF mice. However, no such differences in immune cell populations were observed 
(Paper IV, Figure 6A-I). This suggests that mutations in CFTR may cause immune cell 
dysfunction rather than altering immune cell numbers. 
To gain further mechanistic insight into which of the immune cell population that could be 
affected we looked at the antibody production in response to a TI or TD antigen. We 
observed no difference in antibody production to a TI antigen between wt and CFTRtm1EUR 
mice (Paper IV, Figure 7A). However the antibody production in response to a TD antigen 
was significantly lower in CFTRtm1EUR mice at day 7 post infection (Paper IV, Figure 7B). 
By using this approach, we were also able to follow the antibody development in CFTRtm1EUR 
mice for a longer period of time than that which is possible in the infected mice due to the 
decreased survival of CFTRtm1EUR mice after CVB infection. We observed that at day 12 post 
injection, CFTRtm1EUR mice had reached the same levels of antibodies as the wt mice 
suggesting that there is a delayed production of antibodies rather than an overall lower 
antibody production in the CFTRtm1EUR mice. This delayed induction of neutralizing 
antibodies probably allows the pathogen more time for replication and thus causes more 
severe infections before the immune system is able to control the infection.   
Studies have shown that lymphocytes express CFTR and that defects in CFTR affect immune 
cell responses (221-223). In Paper IV we showed that antibody production to a TD antigen 
was impaired. The response to a TI antigen was normal in the CFTRtm1EUR mice suggesting 
that B cell function, activation and secretion of antibodies is normal in these mice. Defects 
within the T cell population in CF have been reported (179). If defects in the T cell 
population are responsible for the delayed antibody production in response to a TD antigen is 
interesting for follow up studies.  
Nevertheless, we cannot exclude that the delayed antibody production could be a result of 
factors other than a direct effect of the T cells. T cell activation is dependent on interactions 
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with APCs, and mainly DCs. The hypothesis that DCs are affected in CF could be supported 
by our data showing a delayed induction of IFNα after poly I:C stimulation. IFNα is mainly 
produced by pDCs early after infection (224). The data showing that IFNα induction seemed 
to be delayed rather than there being an overall inhibition of its production correlates well 
with the results demonstrating that antibody production is delayed, suggesting that they may 
depend on each other. Studies looking at the function of pulmonary DCs in CF mice have 
shown that low levels of S1P in the lung impair DC function and their T cell stimulatory 
capacity (162). Low levels of S1P have also been observed in the lung of the CFTRtm1EUR 
mouse and this was shown to affect immune cell infiltrates of the lung (225). Indeed, S1P is 
essential for immune cell function (226) and immune cell migration (227-229). CFTR has 
been shown to mediate the uptake of S1P in cells (230). Normally S1P is metabolized quite 
fast and a decreased uptake of S1P in blood by tissue cells have been postulated to result in 
S1P accumulation in the circulation (231). If this occurs in the CFTRtm1EUR mouse remains to 
be studied. However, it seems clear that CFTR has an impact in controlling levels of S1P in 
different parts of the body. Altered S1P levels may result in impaired priming or interaction 
of DC-T cells which could subsequently delay the antibody response of B cells. Given the 
importance of S1P for immune cell migration and activation, studying DC functions and S1P 
levels in the CFTRtm1EUR mouse could be interesting to investigate in future studies.  
To summarize our studies in Paper IV, we showed that CFTRtm1EUR mice have a decreased 
survival and impaired immune response to CVB infection. In addition the antibody 
production to a TD antigen was delayed in CFTRtm1EUR mice. 
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5 CONCLUDING REMARKS 
In this thesis, I aimed to expand our knowledge of innate antiviral immune response 
mechanisms to CVB infections in primary human hepatocytes. In addition, I wanted to 
address strategies through which CVBs can evade the innate immune system in host cells and 
how CVBs cause beta cell dysfunction. Finally, I intended to study how mutations in CFTR 
affect the immune response to CVB infections.  
To conclude: 
Paper I:  Primary human hepatocytes respond to CVB infection by up-regulating type III 
IFN expression. In addition, type III IFNs induce an antiviral state in human 
hepatocytes by up-regulating several ISGs and attenuate CVB replication.  
Paper II:  CVBs have evolved mechanisms to inhibit type III IFN production in infected 
cells by cleaving the adaptor proteins IPS1 and TRIF. This cleavage was 
mediated by the viral protease 2Apro. Evading type III IFNs response 
mechanisms may help CVBs to establish infections at viral entry sites and 
subsequent viral spread thereby causing a systemic infection. 
Paper III:  Insulin secretion from primary human islets and INS1-832/13 cells was 
inhibited by CVB infection. The viral proteins 2Apro, 3A and 3Cpro all inhibited 
exocytosis and had negative effects on hGH expression (2Apro, 3Cpro) or 
glucose stimulated hormone release from INS1-832/13 cells (3A, 3Cpro). 2Apro 
and 3Cpro inhibited exocytosis by decreasing Ca2+ influx. Inhibiting insulin 
secretion from infected cells may be a potential mechanism through which 
CVBs could contribute to T1D after infection.  
Paper IV: Mice carrying the most common CF mutation in humans show a decreased 
survival rate after CVB infection. The mice had higher levels of replicating 
virus in several organs at days 5 and 7 post infection, which seemed to correlate 
with a delayed ability to produce neutralizing antibodies. A delayed antibody 
production to a TD antigen was also observed in CF mice, suggesting that 
CFTR may affect immune cell functions. 
The work conducted in this thesis has contributed to an increase in our knowledge of immune 
response mechanisms during CVB infections and provides clues as to how CVBs can 
contribute to disease pathology. It is of importance for future studies that have the aim of 
developing new antiviral treatments that could prevent severe infections with CVBs and 
mitigate respiratory EV infections in individuals with CF.  
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